C H Lieu1, L A Lambert2, R A Wolff1, C Eng1, N Zhang3, S Wen3, S Rafeeq2, M Taggart4, K Fournier2, R Royal2, P Mansfield2, M J Overman5. 1. Departments of Gastrointestinal Medical Oncology. 2. Departments of Surgical Oncology. 3. Departments of Biostatistics. 4. Departments of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA. 5. Departments of Gastrointestinal Medical Oncology. Electronic address: moverman@mdanderson.org.
Abstract
BACKGROUND: Poorly differentiated and signet ring cell adenocarcinomas of the appendix represent a subset with aggressive tumor biology and poor outcomes with few studies evaluating the impact of systemic chemotherapy and cytoreductive surgery (CRS). PATIENTS AND METHODS: A retrospective chart review of patients with either poorly differentiated and signet ring cell appendiceal adenocarcinomas was completed from 1992 to 2010. RESULTS: One hundred forty-two patients were identified. Seventy-eight patients with metastatic disease received chemotherapy. Radiographic response was 44%, median progression-free survival (PFS) was 6.9 months, and median overall survival (OS) was 1.7 years. In multivariate analysis, response to chemotherapy [hazard ratio (HR) 0.5; P = 0.02] predicted improved PFS, and complete CRS (HR 0.3; P = 0.004) predicted improved OS. Patients who underwent complete CRS (n = 26) had a median relapse-free survival (RFS) of 1.2 years and a median OS of 4.2 years. In multivariate analysis for this subset, complete cytoreduction score of 0 was significantly correlated with improved RFS (HR 0.07; P = 0.01) and OS (HR 0.02; P = 0.01). CONCLUSIONS: Systemic chemotherapy appears to be a viable treatment option for patients with metastatic poorly differentiated and signet ring cell appendiceal adenocarcinomas. Complete CRS is associated with improved RFS and OS, though part of this benefit likely reflects the selection of good tumor biology.
BACKGROUND: Poorly differentiated and signet ring cell adenocarcinomas of the appendix represent a subset with aggressive tumor biology and poor outcomes with few studies evaluating the impact of systemic chemotherapy and cytoreductive surgery (CRS). PATIENTS AND METHODS: A retrospective chart review of patients with either poorly differentiated and signet ring cell appendiceal adenocarcinomas was completed from 1992 to 2010. RESULTS: One hundred forty-two patients were identified. Seventy-eight patients with metastatic disease received chemotherapy. Radiographic response was 44%, median progression-free survival (PFS) was 6.9 months, and median overall survival (OS) was 1.7 years. In multivariate analysis, response to chemotherapy [hazard ratio (HR) 0.5; P = 0.02] predicted improved PFS, and complete CRS (HR 0.3; P = 0.004) predicted improved OS. Patients who underwent complete CRS (n = 26) had a median relapse-free survival (RFS) of 1.2 years and a median OS of 4.2 years. In multivariate analysis for this subset, complete cytoreduction score of 0 was significantly correlated with improved RFS (HR 0.07; P = 0.01) and OS (HR 0.02; P = 0.01). CONCLUSIONS: Systemic chemotherapy appears to be a viable treatment option for patients with metastatic poorly differentiated and signet ring cell appendiceal adenocarcinomas. Complete CRS is associated with improved RFS and OS, though part of this benefit likely reflects the selection of good tumor biology.
Authors: Thomas J Miner; Jinru Shia; David P Jaques; David S Klimstra; Murray F Brennan; Daniel G Coit Journal: Ann Surg Date: 2005-02 Impact factor: 12.969
Authors: Jamie F Shapiro; Judy L Chase; Robert A Wolff; Laura A Lambert; Paul F Mansfield; Michael J Overman; Aki Ohinata; Jun Liu; Xuemei Wang; Cathy Eng Journal: Cancer Date: 2010-01-15 Impact factor: 6.860
Authors: Joseph Misdraji; Rhonda K Yantiss; Fiona M Graeme-Cook; Ulysses J Balis; Robert H Young Journal: Am J Surg Pathol Date: 2003-08 Impact factor: 6.394
Authors: A L Farquharson; N Pranesh; G Witham; R Swindell; M B Taylor; A G Renehan; S Rout; M S Wilson; S T O'Dwyer; M P Saunders Journal: Br J Cancer Date: 2008-08-19 Impact factor: 7.640
Authors: Nick C Levinsky; Mackenzie C Morris; Koffi Wima; Jeffrey J Sussman; Syed A Ahmad; Jordan M Cloyd; Charles Kimbrough; Keith Fournier; Andrew Lee; Sean Dineen; Sophie Dessureault; Jula Veerapong; Joel M Baumgartner; Callisia Clarke; Mohammad Y Zaidi; Charles A Staley; Shishir K Maithel; Jennifer Leiting; Travis Grotz; Laura Lambert; Ryan J Hendrix; Sean Ronnekleiv-Kelly; Courtney Pokrzywa; Mustafa Raoof; Oliver S Eng; Fabian M Johnston; Jonathan Greer; Sameer H Patel Journal: J Gastrointest Surg Date: 2019-08-19 Impact factor: 3.452
Authors: P Barrios; F Losa; S Gonzalez-Moreno; A Rojo; A Gómez-Portilla; P Bretcha-Boix; I Ramos; J Torres-Melero; R Salazar; M Benavides; T Massuti; E Aranda Journal: Clin Transl Oncol Date: 2015-10-21 Impact factor: 3.405
Authors: Konstantinos I Votanopoulos; Greg Russell; Reese W Randle; Perry Shen; John H Stewart; Edward A Levine Journal: Ann Surg Oncol Date: 2014-10-16 Impact factor: 5.344
Authors: S Joseph Sirintrapun; Aaron U Blackham; Greg Russell; Konstantinos Votanopoulos; John H Stewart; Perry Shen; Edward A Levine; Kim R Geisinger; Simon Bergman Journal: Hum Pathol Date: 2014-04-04 Impact factor: 3.466
Authors: Edward A Levine; Konstantinos I Votanopoulos; Perry Shen; Greg Russell; Joyce Fenstermaker; Paul Mansfield; David Bartlett; John H Stewart Journal: J Am Coll Surg Date: 2018-01-10 Impact factor: 6.113